Literature DB >> 27787746

Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation.

Ryoji Kobayashi1, Tetsuo Mitsui2, Naoto Fujita3, Tomoo Osumi4, Tomohiro Aoki5, Kazunari Aoki6, Ritsuro Suzuki7, Takahiro Fukuda8, Toshihiro Miyamoto9, Koji Kato10, Hirohisa Nakamae11, Hiroaki Goto12, Tetsuya Eto13, Masami Inoue14, Takehiko Mori15, Kiminori Terui16, Masahito Onizuka17, Katsuyoshi Koh18, Yuhki Koga19, Tatsuo Ichinohe20, Akihisa Sawada14, Yoshiko Atsuta21, Junji Suzumiya7.   

Abstract

Several studies of patients with acute lymphoblastic leukemia and acute myeloid leukemia who received stem cell transplantation (SCT) have reported that adolescents and young adults (AYAs) experience higher transplant-related mortality than that in younger children. However, to the best of our knowledge, there have been no reports of a similar comparison of non-Hodgkin lymphoma (NHL) patients who received SCT. We analyzed 918 patients aged 30 years and younger who received their first stem cell transplantation for NHL. Of the allogeneic transplant patients, children and AYAs did not significantly differ in survival rate, event-free survival rate, relapse rate, or transplant-related mortality. However, 5-year transplant-related mortality after autologous transplantation was significantly higher in children than in AYAs (5.1% in children vs. 0.8% in AYAs, P = 0.0043). The cause of transplant-related death in three of four children was interstitial pneumonitis. In NHL patients, transplantation results in AYAs were not inferior than those in children.

Entities:  

Keywords:  AYA; Non-Hodgkin lymphoma; Stem cell transplantation

Mesh:

Year:  2016        PMID: 27787746     DOI: 10.1007/s12185-016-2120-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

1.  Rituximab-induced acute pulmonary fibrosis.

Authors:  Rafael J Leon; Americo Gonsalvo; Rafael Salas; Nelly C Hidalgo
Journal:  Mayo Clin Proc       Date:  2004-07       Impact factor: 7.616

2.  Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children.

Authors:  H Sano; R Kobayashi; A Iguchi; D Suzuki; K Kishimoto; K Yasuda; K Kobayashi
Journal:  Bone Marrow Transplant       Date:  2013-08-19       Impact factor: 5.483

3.  Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia.

Authors:  Navneet S Majhail; Ruta Brazauskas; Anna Hassebroek; Christopher N Bredeson; Theresa Hahn; Gregory A Hale; Mary M Horowitz; Hillard M Lazarus; Richard T Maziarz; William A Wood; Susan K Parsons; Steven Joffe; J Douglas Rizzo; Stephanie J Lee; Brandon M Hayes-Lattin
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-29       Impact factor: 5.742

4.  Neutrophil stimulation with granulocyte colony-stimulating factor worsens ventilator-induced lung injury and mortality in rats.

Authors:  Waheedullah Karzai; Xizhong Cui; Norbert Heinicke; Christian Niemann; Eric P Gerstenberger; Rosaly Correa; Steven Banks; Bjoern Mehlhorn; Frank Bloos; Konrad Reinhart; Peter Q Eichacker
Journal:  Anesthesiology       Date:  2005-11       Impact factor: 7.892

5.  Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.

Authors:  T A Davis; C A White; A J Grillo-López; W S Velásquez; B Link; D G Maloney; R O Dillman; M E Williams; A Mohrbacher; R Weaver; S Dowden; R Levy
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

6.  Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphoma.

Authors:  Harumi Kato; Kazuhito Yamamoto; Hirofumi Taji; Yasuhiro Oki; Dai Chihara; Masao Seto; Yoshitoyo Kagami; Yasuo Morishima
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-10-05

7.  First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.

Authors:  John D Hainsworth; Sharlene Litchy; M Ray Lamb; Gladys I Rodriguez; Carroll Scroggin; F Anthony Greco
Journal:  Clin Lymphoma       Date:  2003-06

8.  Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.

Authors:  Michael J Burke; Nathan Gossai; John E Wagner; Angela R Smith; Veronika Bachanova; Qing Cao; Margaret L MacMillan; Heather S Stefanski; Daniel J Weisdorf; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2012-09-06       Impact factor: 5.742

9.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

10.  Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation.

Authors:  M J Burke; N Gossai; Q Cao; M L Macmillan; E Warlick; M R Verneris
Journal:  Bone Marrow Transplant       Date:  2013-11-04       Impact factor: 5.483

  10 in total
  2 in total

1.  Quality-of-Life Trajectories in Adolescent and Young Adult versus Older Adult Allogeneic Hematopoietic Cell Transplantation Recipients.

Authors:  Reema R Mathanda; Betty K Hamilton; Lisa Rybicki; Anjali S Advani; Amy Colver; Jane Dabney; Christina Ferraro; Rabi Hanna; Matt Kalaycio; Christine Lawrence; Linda McLellan; Ronald Sobecks; Navneet S Majhail; Seth J Rotz
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-19       Impact factor: 5.742

2.  Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma.

Authors:  Naoto Fujita; Ryoji Kobayashi; Yoshiko Atsuta; Fuminori Iwasaki; Junji Suzumiya; Yoji Sasahara; Masami Inoue; Katsuyoshi Koh; Tsukasa Hori; Hiroaki Goto; Tatsuo Ichinohe; Yoshiko Hashii; Koji Kato; Ritsuro Suzuki; Tetsuo Mitsui
Journal:  Int J Hematol       Date:  2019-01-30       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.